How has been the historical performance of Strides Pharma?

Answer:Strides Pharma has shown a significant improvement in its financial performance over the years, particularly in the fiscal year ending March 2025.

Breakdown:
In the fiscal year ending March 2025, Strides Pharma reported net sales of 4,565.34 crore, a notable increase from 3,890.13 crore in March 2024 and 3,688.39 crore in March 2023. The total operating income also rose to 4,565.34 crore, reflecting a consistent upward trend from previous years. The company's total expenditure, excluding depreciation, increased to 3,762.52 crore, up from 3,307.75 crore in March 2024. This resulted in an operating profit (PBDIT) of 802.82 crore, a significant rise from 582.38 crore the previous year. The profit before tax turned positive at 485.08 crore, recovering from a loss of 60.83 crore in March 2024. Consequently, the profit after tax reached 407.57 crore, a substantial recovery from a loss of 89.94 crore in the prior year. The earnings per share (EPS) also improved dramatically to 389.92 from a negative EPS of -3.37 in March 2024. On the balance sheet, total assets increased to 5,779.59 crore, while total liabilities rose slightly to 5,779.59 crore, indicating a stable financial position. The cash flow from operating activities was positive at 684.00 crore, although the net cash outflow was recorded at -48.00 crore. Overall, Strides Pharma's financial metrics indicate a strong recovery and growth trajectory in its recent performance.